Nuzhat Ahmed

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1619071/publications.pdf

Version: 2024-02-01

50 papers	4,105 citations	147566 31 h-index	205818 48 g-index
50 all docs	50 docs citations	50 times ranked	5986 citing authors

#	Article	IF	Citations
1	The attributes of plakins in cancer and disease: perspectives on ovarian cancer progression, chemoresistance and recurrence. Cell Communication and Signaling, 2021, 19, 55.	2.7	14
2	Determinants of resistance to VEGF-TKI and immune checkpoint inhibitors in metastatic renal cell carcinoma. Journal of Experimental and Clinical Cancer Research, 2021, 40, 186.	3.5	77
3	Expression of TIMPs and MMPs in Ovarian Tumors, Ascites, Ascites-Derived Cells, and Cancer Cell Lines: Characteristic Modulatory Response Before and After Chemotherapy Treatment. Frontiers in Oncology, 2021, 11, 796588.	1.3	12
4	TIMP-2 regulates proliferation, invasion and STAT3-mediated cancer stem cell-dependent chemoresistance in ovarian cancer cells. BMC Cancer, 2020, 20, 960.	1.1	21
5	Ovarian Cancer, Cancer Stem Cells and Current Treatment Strategies: A Potential Role of Magmas in the Current Treatment Methods. Cells, 2020, 9, 719.	1.8	43
6	Paclitaxel-Induced Src Activation Is Inhibited by Dasatinib Treatment, Independently of Cancer Stem Cell Properties, in a Mouse Model of Ovarian Cancer. Cancers, 2019, 11, 243.	1.7	10
7	Tumour microenvironment and metabolic plasticity in cancer and cancer stem cells: Perspectives on metabolic and immune regulatory signatures in chemoresistant ovarian cancer stem cells. Seminars in Cancer Biology, 2018, 53, 265-281.	4.3	127
8	Paclitaxel-Loaded Self-Assembled Lipid Nanoparticles as Targeted Drug Delivery Systems for the Treatment of Aggressive Ovarian Cancer. ACS Applied Materials & Interfaces, 2018, 10, 25174-25185.	4.0	102
9	The Many Facets of Metzincins and Their Endogenous Inhibitors: Perspectives on Ovarian Cancer Progression. International Journal of Molecular Sciences, 2018, 19, 450.	1.8	13
10	Momelotinib decreased cancer stem cell associated tumor burden and prolonged disease-free remission period in a mouse model of human ovarian cancer. Oncotarget, 2018, 9, 16599-16618.	0.8	27
11	Knockdown of stem cell regulator Oct4A in ovarian cancer reveals cellular reprogramming associated with key regulators of cytoskeleton-extracellular matrix remodelling. Scientific Reports, 2017, 7, 46312.	1.6	18
12	Coalition of Oct4A and Î²1 integrins in facilitating metastasis in ovarian cancer. BMC Cancer, 2016, 16, 432.	1.1	14
13	Unique proteome signature of post-chemotherapy ovarian cancer ascites-derived tumor cells. Scientific Reports, 2016, 6, 30061.	1.6	33
14	A critical role of Oct4A in mediating metastasis and disease-free survival in a mouse model of ovarian cancer. Molecular Cancer, 2015, 14, 152.	7.9	26
15	Enhanced activation of STAT3 in ascites-derived recurrent ovarian tumors: inhibition of cisplatin-induced STAT3 activation reduced tumorigenicity of ovarian cancer by a loss of cancer stem cell-like characteristics. Journal of Cancer Stem Cell Research, 2015, 3, 1.	1.1	6
16	Targeted Disruption of the JAK2/STAT3 Pathway in Combination with Systemic Administration of Paclitaxel Inhibits the Priming of Ovarian Cancer Stem Cells Leading to a Reduced Tumor Burden. Frontiers in Oncology, 2014, 4, 75.	1.3	62
17	Ovarian cancer stem cells: Molecular concepts and relevance as therapeutic targets. Molecular Aspects of Medicine, 2014, 39, 110-125.	2.7	72
18	Betaglycan blocks metastatic behaviors in human granulosa cell tumors by suppressing NFÎºB-mediated induction of MMP2. Cancer Letters, 2014, 354, 107-114.	3.2	20

#	Article	IF	Citations
19	Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden. BMC Cancer, 2014, 14, 317.	1.1	105
20	Distinct molecular signature of recurrent ovarian tumor cells isolated from the ascites of advanced-stage serous ovarian cancer patients. Journal of Cancer Stem Cell Research, 2014, 1, 1.	1.1	3
21	Short-term single treatment of chemotherapy results in the enrichment of ovarian cancer stem cell-like cells leading to an increased tumor burden. Molecular Cancer, 2013, 12, 24.	7.9	179
22	Cancerous ovarian stem cells: Obscure targets for therapy but relevant to chemoresistance. Journal of Cellular Biochemistry, 2013, 114, 21-34.	1.2	90
23	Investigation of human cationic antimicrobial protein-18 (hCAP-18), lactoferrin and CD163 as potential biomarkers for ovarian cancer. Journal of Ovarian Research, 2013, 6, 5.	1.3	16
24	Getting to Know Ovarian Cancer Ascites: Opportunities for Targeted Therapy-Based Translational Research. Frontiers in Oncology, 2013, 3, 256.	1.3	358
25	Attributes of Oct4 in stem cell biology: perspectives on cancer stem cells of the ovary. Journal of Ovarian Research, 2012, 5, 37.	1.3	52
26	Isolation and Characterization of Tumor Cells from the Ascites of Ovarian Cancer Patients: Molecular Phenotype of Chemoresistant Ovarian Tumors. PLoS ONE, 2012, 7, e46858.	1.1	188
27	Contribution of Fibroblast and Mast Cell (Afferent) and Tumor (Efferent) IL-6 Effects within the Tumor Microenvironment. Cancer Microenvironment, 2012, 5, 83-93.	3.1	59
28	2D-PAGE of ovarian cancer: Analysis of soluble and insoluble fractions using medium-range immobilized pH gradients. Biochemical and Biophysical Research Communications, 2011, 406, 408-413.	1.0	23
29	Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-like profile. Journal of Cellular Biochemistry, 2011, 112, 2850-2864.	1.2	202
30	Neuronal transcription factor Brn-3a(l) is over expressed in high-grade ovarian carcinomas and tumor cells from ascites of patients with advanced-stage ovarian cancer. Journal of Ovarian Research, 2010, 3, 17.	1.3	9
31	Epithelial Mesenchymal Transition and Cancer Stem Cell-Like Phenotypes Facilitate Chemoresistance in Recurrent Ovarian Cancer. Current Cancer Drug Targets, 2010, 10, 268-278.	0.8	201
32	Multicellular spheroids in ovarian cancer metastases: Biology and pathology. Gynecologic Oncology, 2009, 113, 143-148.	0.6	336
33	Epidermal growth factor-induced ovarian carcinoma cell migration is associated with JAK2/STAT3 signals and changes in the abundance and localization of Î±6Î²1 integrin. International Journal of Biochemistry and Cell Biology, 2009, 41, 1034-1045.	1.2	47
34	Î±2Î²1 integrin affects metastatic potential of ovarian carcinoma spheroids by supporting disaggregation and proteolysis. Journal of Carcinogenesis, 2007, 6, 11.	2.5	103
35	Neutrophil gelatinase-associated lipocalin (NGAL) an early-screening biomarker for ovarian cancer: NGAL is associated with epidermal growth factor-induced epithelio-mesenchymal transition. International Journal of Cancer, 2007, 120, 2426-2434.	2.3	151
36	Epithelialâ€“mesenchymal interconversions in normal ovarian surface epithelium and ovarian carcinomas: An exception to the norm. Journal of Cellular Physiology, 2007, 213, 581-588.	2.0	208

#	Article	IF	Citations
37	Molecular pathways regulating EGF-induced epithelio-mesenchymal transition in human ovarian surface epithelium. American Journal of Physiology - Cell Physiology, 2006, 290, C1532-C1542.	2.1	173
38	15 Role of Integrins in Ovarian Cancer. Handbook of Immunohistochemistry and in Situ Hybridization of Human Carcinomas, 2005, 4, 425-439.	0.0	0
39	Strategies for revealing lower abundance proteins in two-dimensional protein maps. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2005, 815, 39-50.	1.2	58
40	Role of Integrin Receptors for Fibronectin, Collagen and Laminin in the Regulation of Ovarian Carcinoma Functions in Response to a Matrix Microenvironment. Clinical and Experimental Metastasis, 2005, 22, 391-402.	1.7	117
41	Proteomic tracking of serum protein isoforms as screening biomarkers of ovarian cancer. Proteomics, 2005, 5, 4625-4636.	1.3	94
42	Cell-Free 59 kDa Immunoreactive Integrin-Linked Kinase. Clinical Cancer Research, 2004, 10, 2415-2420.	3.2	42
43	Expression and localization of ÂvÂ6 integrin in extraplacental fetal membranes: possible role in human parturition. Molecular Human Reproduction, 2004, 10, 173-179.	1.3	11
44	An approach to remove albumin for the proteomic analysis of low abundance biomarkers in human serum. Proteomics, 2003, 3, 1980-1987.	1.3	193
45	Proteomic profiling of proteins associated with urokinase plasminogen activator receptor in a colon cancer cell line using an antisense approach. Proteomics, 2003, 3, 288-298.	1.3	22
46	Integrin-linked kinase expression increases with ovarian tumour grade and is sustained by peritoneal tumour fluid. Journal of Pathology, 2003, 201, 229-237.	2.1	121
47	Î±_vÎ²₆Integrin-A Marker for the Malignant Potential of Epithelial Ovarian Cancer. Journal of Histochemistry and Cytochemistry, 2002, 50, 1371-1379.	1.3	94
48	Association between ?v?6 integrin expression, elevated p42/44 kDa MAPK, and plasminogen-dependent matrix degradation in ovarian cancer. Journal of Cellular Biochemistry, 2002, 84, 675-686.	1.2	58
49	Direct integrin Î±vÎ²6-ERK binding: implications for tumour growth. Oncogene, 2002, 21, 1370-1380.	2.6	90
50	Precision Medicine: An Optimal Approach to Patient Care in Renal Cell Carcinoma. Frontiers in Medicine, 0, 9, .	1.2	5